Skip to main content
. 2011 Oct 21;37(ACS-6):1–68. doi: 10.14745/ccdr.v37i00a06
ACS Acute coronary syndrome
AEs Adverse events
BCG Bacille Calmette-Guérin
CCDR Canada Communicable Disease Report
CHMP Committee for Medical Products for Human Use
CI Confidence interval
CVA cerebrovascular accident
DB double blind
EMEA European Medicines Evaluation Agency
GBS Guillain-Barré syndrome
GMT Geometric mean titre
GMR geometric mean titre ratio
HA Haemagglutinin antigen
HI Haemagglutination inhibition
ID Intradermal
ITT intention-to-treat
IgE Immune globulin E
IM Intramuscular
MFI mean-fold increase
mL Millilitres
mm Millimitre
MN microneutralization
NACI National Advisory Committee on Immunization
NS not significant
NT neutralization
ORS Oculorespiratory syndrome
pH1N1 Pandemic H1N1
RCT randomized controlled trial
SRH Single radial haemolysis
TIV Trivalent inactivated influenza vaccine
TIV-ID Trivalent inactivated influenza vaccine administered by the intradermal route
µg Microgram
WHO World Health Organization